151 related articles for article (PubMed ID: 1285327)
1. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies.
Frödin JE; Lefvert AK; Mellstedt H
Cell Biophys; 1992; 21(1-3):153-65. PubMed ID: 1285327
[TBL] [Abstract][Full Text] [Related]
2. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?
Frödin JE; Faxas ME; Hagström B; Lefvert AK; Masucci G; Nilsson B; Steinitz M; Unger P; Mellstedt H
Hybridoma; 1991 Aug; 10(4):421-31. PubMed ID: 1937495
[TBL] [Abstract][Full Text] [Related]
3. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.
Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
Cancer Immunol Immunother; 1995 Jun; 40(6):367-75. PubMed ID: 7627993
[TBL] [Abstract][Full Text] [Related]
5. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.
Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 1996 Feb; 42(2):81-7. PubMed ID: 8620524
[TBL] [Abstract][Full Text] [Related]
6. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?
Fagerberg J; Frödin JE; Wigzell H; Mellstedt H
Cancer Immunol Immunother; 1993 Sep; 37(4):264-70. PubMed ID: 8348565
[TBL] [Abstract][Full Text] [Related]
7. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?
Fagerberg J; Frödin JE; Ragnhammar P; Steinitz M; Wigzell H; Mellstedt H
Cancer Immunol Immunother; 1994 Mar; 38(3):149-59. PubMed ID: 8124683
[TBL] [Abstract][Full Text] [Related]
8. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma.
Baum RP; Niesen A; Hertel A; Nancy A; Hess H; Donnerstag B; Sykes TR; Sykes CJ; Suresh MR; Noujaim AA
Cancer; 1994 Feb; 73(3 Suppl):1121-5. PubMed ID: 8306256
[TBL] [Abstract][Full Text] [Related]
9. The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma.
Mellstedt H; Frödin JE; Ragnhammar P; Masucci G; Shetye J; Christensson B; Biberfeld P; Makower J; Pihlstedt P; Cedermark B
Med Oncol Tumor Pharmacother; 1989; 6(1):99-107. PubMed ID: 2786122
[TBL] [Abstract][Full Text] [Related]
10. Anti-idiotypic antibodies to monoclonal antibody CO17-1A.
Herlyn D; Sears H; Iliopoulos D; Lubeck M; Douillard JY; Sindelar W; Tempero M; Mellstedt H; Maher M; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S51-8. PubMed ID: 3488951
[TBL] [Abstract][Full Text] [Related]
11. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies.
Dillman RO; Shawler DL; McCallister TJ; Halpern SE
Cancer Biother; 1994; 9(1):17-28. PubMed ID: 7812354
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients.
Herlyn D; Harris D; Zaloudik J; Sperlagh M; Maruyama H; Jacob L; Kieny MP; Scheck S; Somasundaram R; Hart E
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):303-11. PubMed ID: 8061902
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulating IL-6 activity by murine monoclonal antibodies.
Brochier J; Legouffe E; Liautard J; Gaillard JP; Mao LQ; Bataille R; Rossi JF; Klein B
Int J Immunopharmacol; 1995 Jan; 17(1):41-8. PubMed ID: 7782152
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cancer patients' immune responses by anti-idiotypic antibodies.
Herlyn D; Wettendorff M; Koprowski H
Int Rev Immunol; 1989; 4(4):347-57. PubMed ID: 2519932
[TBL] [Abstract][Full Text] [Related]
15. Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients.
Birebent B; Koido T; Mitchell E; Li W; Somasundaram R; Purev E; Hoey D; Mastrangelo M; Maguire H; Harris DT; Nair S; Cai E; Herlyn D
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R27-33. PubMed ID: 11768621
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.
Dhingra K; Fritsche H; Murray JL; LoBuglio AF; Khazaeli MB; Kelley S; Tepper MA; Grasela D; Buzdar A; Valero V
Cancer Res; 1995 Jul; 55(14):3060-7. PubMed ID: 7606728
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas.
Frödin JE; Harmenberg U; Biberfeld P; Christensson B; Lefvert AK; Rieger A; Shetye J; Wahren B; Mellstedt H
Hybridoma; 1988 Aug; 7(4):309-21. PubMed ID: 3262566
[TBL] [Abstract][Full Text] [Related]
19. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
Madiyalakan R; Sykes TR; Dharampaul S; Sykes CJ; Baum RP; Hör G; Noujaim AA
Hybridoma; 1995 Apr; 14(2):199-203. PubMed ID: 7590780
[TBL] [Abstract][Full Text] [Related]
20. Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer.
Herlyn D; Somasundaram R; Zaloudik J; Jacob L; Harris D; Kieny MP; Sears H; Mastrangelo M
Cell Biophys; 1994; 24-25():143-53. PubMed ID: 7736518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
